{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:27:10Z","timestamp":1788838030032,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ccc.2021.11.007","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:14:01Z","timestamp":1648750441000},"page":"393-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Autoimmune Encephalitis: Distinguishing Features and Specific Therapies"],"prefix":"10.1016","volume":"38","author":[{"given":"Dominic O.","family":"Co","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ccc.2021.11.007_bib1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis Consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-015-0529-1","article-title":"Autoimmune encephalitis and its relation to infection","volume":"15","author":"Venkatesan","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ccc.2021.11.007_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2017.01.023","article-title":"Anti-N-Methyl-d-aspartate receptor encephalitis appearing as a new-onset psychosis: disease course in children and adolescents within the California encephalitis project","volume":"72","author":"Gable","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.007_bib5","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1212\/WNL.0000000000006990","article-title":"Autoimmune encephalitis: a costly condition","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12028-015-0196-8","article-title":"Autoimmune encephalitis in the ICU: analysis of phenotypes, serologic findings, and outcomes","volume":"24","author":"Mittal","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.ccc.2021.11.007_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2020.11.014","article-title":"Clinical features, treatment strategies, and outcomes in hospitalized children with immune-mediated encephalopathies","volume":"116","author":"McGetrick","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.007_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.0b013e3182a2cc6d","article-title":"Predictors of outcome in acute encephalitis","volume":"81","author":"Thakur","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A\u00a0clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000663","article-title":"Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient","volume":"7","author":"Cellucci","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"7","key":"10.1016\/j.ccc.2021.11.007_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pcl.2016.08.005","article-title":"Immune-mediated diseases of the central nervous system: a specificity-focused diagnostic paradigm","volume":"64","author":"Co","year":"2017","journal-title":"Pediatr Clin North Am"},{"issue":"11","key":"10.1016\/j.ccc.2021.11.007_bib13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.007_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MOP.0b013e3283402d2f","article-title":"Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents","volume":"22","author":"Florance-Ryan","year":"2010","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.007_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000002","article-title":"NMDA receptor antibodies associated with distinct white matter syndromes","volume":"1","author":"Hacohen","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.007_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"van Sonderen","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ana.25310","article-title":"LGI1 and CASPR2 neurological autoimmunity in children","volume":"84","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.007_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.007_bib22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/brain\/awz094","article-title":"The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies","volume":"142","author":"van Coevorden-Hameete","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.ccc.2021.11.007_bib24","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABA(A) receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"issue":"9 Suppl 2","key":"10.1016\/j.ccc.2021.11.007_bib25","first-page":"S38","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.007_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-0039-1693152","article-title":"Diagnostic considerations in acute disseminated encephalomyelitis and the interface with MOG antibody","volume":"50","author":"Santoro","year":"2019","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ccc.2021.11.007_bib29","doi-asserted-by":"crossref","first-page":"102538","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/epi.14022","article-title":"New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives","volume":"59","author":"Gaspard","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.ccc.2021.11.007_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12974-018-1063-2","article-title":"Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade","volume":"15","author":"DeSena","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.007_bib33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Super-refractory status epilepticus and febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib34","first-page":"135","article-title":"Febrile infection-related epilepsy syndrome treated successfully with anakinra in a 21-year-old woman","volume":"118","author":"Westbrook","year":"2019","journal-title":"WMJ"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40478-019-0693-7","article-title":"Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis","volume":"7","author":"Chefdeville","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/WCO.0000000000000087","article-title":"Autoimmune encephalitis as differential diagnosis of infectious encephalitis","volume":"27","author":"Armangue","year":"2014","journal-title":"Curr Opin Neurol"},{"issue":"Pt 5","key":"10.1016\/j.ccc.2021.11.007_bib37","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain J Neurol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib38","first-page":"22","article-title":"Ovarian Teratoma and N-Methyl-D-aspartate receptor autoimmune encephalitis: insights into imaging diagnosis of teratoma and timing of surgery","volume":"10","author":"Thiyagarajan","year":"2021","journal-title":"J\u00a0Clin Gynecol Obstet"},{"issue":"Suppl 3","key":"10.1016\/j.ccc.2021.11.007_bib39","first-page":"3","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.ccc.2021.11.007_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12098-015-1988-8","article-title":"Childhood anti-NMDA receptor encephalitis","volume":"83","author":"Suthar","year":"2016","journal-title":"Indian J Pediatr"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejpn.2015.02.006","article-title":"Paediatric anti-N-methyl-d-aspartate receptor encephalitis: the first Italian multicenter case series","volume":"19","author":"Sartori","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pedneo.2018.10.006","article-title":"Immunotherapy for anti-NMDA receptor encephalitis: experience from a single center in Taiwan","volume":"60","author":"Kong","year":"2019","journal-title":"Pediatr Neonatol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain J Neurol"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.007_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0883073820923834","article-title":"Autoimmune encephalitis in children: a case series at a tertiary care center","volume":"35","author":"Rutatangwa","year":"2020","journal-title":"J\u00a0Child Neurol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/JNN.0000000000000450","article-title":"Successful intrathecal rituximab administration in refractory nonteratoma anti\u2013N-Methyl-D-Aspartate receptor encephalitis: a case report","volume":"51","author":"Casares","year":"2019","journal-title":"J\u00a0Neurosci Nurs"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40674-018-0089-z","article-title":"An update on the treatment of pediatric autoimmune encephalitis","volume":"4","author":"Stingl","year":"2018","journal-title":"Curr Treat Options Rheumatol"},{"issue":"8","key":"10.1016\/j.ccc.2021.11.007_bib47","doi-asserted-by":"crossref","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.ccc.2021.11.007_bib48","first-page":"824","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.ccc.2021.11.007_bib49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2018.07.016","article-title":"Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases","volume":"86","author":"Randell","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.ccc.2021.11.007_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2021.05.006","article-title":"B\u00a0cells as target for immunotherapy in rheumatic diseases - current status","volume":"236","author":"Bryl","year":"2021","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ccc.2021.11.007_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pediatrneurol.2019.09.004","article-title":"Bortezomib-responsive refractory anti-N-Methyl-d-Aspartate receptor encephalitis","volume":"103","author":"Cordani","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ccc.2021.11.007_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clineuro.2018.06.005","article-title":"Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis","volume":"172","author":"Schroeder","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.ccc.2021.11.007_bib54","first-page":"2462","article-title":"Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review","volume":"267","author":"Lazzarin","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ccc.2021.11.007_bib55","doi-asserted-by":"crossref","first-page":"577527","DOI":"10.1016\/j.jneuroim.2021.577527","article-title":"Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study","volume":"354","author":"Wang","year":"2021","journal-title":"J\u00a0Neuroimmunol"},{"issue":"1","key":"10.1016\/j.ccc.2021.11.007_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14728222.2021.1856370","article-title":"Autoimmune encephalitis: novel therapeutic targets at the preclinical level","volume":"25","author":"Sell","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"17","key":"10.1016\/j.ccc.2021.11.007_bib57","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J\u00a0Neurosci"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(99)00259-3","article-title":"Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor","volume":"104","author":"Papanastasiou","year":"2000","journal-title":"J\u00a0Neuroimmunol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.007_bib59","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/aws092","article-title":"Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis","volume":"135","author":"Mikasova","year":"2012","journal-title":"Brain"},{"issue":"Pt A","key":"10.1016\/j.ccc.2021.11.007_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuropharm.2016.07.037","article-title":"Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences","volume":"112","author":"Hackos","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.ccc.2021.11.007_bib61","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/brain\/awaa195","article-title":"Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis","volume":"143","author":"Mannara","year":"2020","journal-title":"Brain J Neurol"},{"issue":"Pt 10","key":"10.1016\/j.ccc.2021.11.007_bib62","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain J Neurol"},{"issue":"23","key":"10.1016\/j.ccc.2021.11.007_bib63","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A\u00a0single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.007_bib64","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","article-title":"The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment","volume":"96","author":"Durongpisitkul","year":"1995","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ccc.2021.11.007_bib65","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","article-title":"Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose","volume":"131","author":"Terai","year":"1997","journal-title":"J\u00a0Pediatr"},{"issue":"12","key":"10.1016\/j.ccc.2021.11.007_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ccc.2021.11.007_bib67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ccc.2021.11.007_bib68","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.ccc.2021.11.007_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ana.25421","article-title":"Development of the clinical assessment scale in autoimmune encephalitis","volume":"85","author":"Lim","year":"2019","journal-title":"Ann Neurol"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070421000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:16:27Z","timestamp":1760062587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070421000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0749070421000932"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2021.11.007","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Encephalitis: Distinguishing Features and Specific Therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}